Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon β in dermatomyositis

British Journal of Dermatology

Volumn 176, Issue 5, 2017, Pages 1224-1230

  Huard, C ^a   Gulla S V ^a   Bennett, D V ^a   Coyle, A J ^a   Vleugels, R A ^b   Greenberg, S A ^c,d  

^a PFIZER INC   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BIOLOGICAL MARKER; INTERFERON; RNA; CXCL10 PROTEIN, HUMAN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MESSENGER RNA;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CUTANEOUS DERMATOMYOSITIS DISEASE AREA AND SEVERITY INDEX; DERMATOMYOSITIS; DISEASE ACTIVITY; DISEASE ASSESSMENT; DISEASE SEVERITY; FEMALE; GENE EXPRESSION PROFILING; HUMAN; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RNA ISOLATION; RNA SEQUENCE; SKIN DISEASE; BLOOD; CROSS-SECTIONAL STUDY; GENETICS; METABOLISM; MIDDLE AGED; NORMAL HUMAN; PROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX;

BIOMARKERS; CHEMOKINE CXCL10; CROSS-SECTIONAL STUDIES; DERMATOMYOSITIS; FEMALE; HEALTHY VOLUNTEERS; HUMANS; INTERFERON TYPE I; INTERFERON-BETA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX;

EID: 85015197044     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.15006     Document Type: Article

References (34)

1. Tezak Z, Hoffman EP, Lutz JL et al. Gene expression profiling in DQA1*0501 + children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol 2002; 168:4154–63.
2. Greenberg SA, Sanoudou D, Haslett JN et al. Molecular profiles of inflammatory myopathies. Neurology 2002; 59:1170–82.
3. Greenberg SA, Pinkus JL, Pinkus GS et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005; 57:664–78.
4. Salajegheh M, Kong SW, Pinkus JL et al. Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy. Ann Neurol 2010; 67:53–63.
5. Cappelletti C, Baggi F, Zolezzi F et al. Type I interferon and Toll-like receptor expression characterizes inflammatory myopathies. Neurology 2011; 76:2079–88.
6. Suarez-Calvet X, Gallardo E, Nogales-Gadea G et al. Altered RIG-I/DDX58-mediated innate immunity in dermatomyositis. J Pathol 2014; 233:258–68.
7. Walsh RJ, Kong SW, Yao Y et al. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum 2007; 56:3784–92.
8. Wong D, Kea B, Pesich R et al. Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases. PLOS ONE 2012; 7:e29161.
9. Greenberg SA, Higgs BW, Morehouse C et al. Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis. Genes Immun 2012; 13:207–13.
10. Higgs BW, Zhu W, Morehouse C et al. A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis 2014; 73:256–62.
11. Yao Y, Richman L, Higgs BW et al. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009; 60:1785–96.
12. Merrill JT, Wallace DJ, Petri M et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis 2011; 70:1905–13.
13. McBride JM, Jiang J, Abbas AR et al. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum 2012; 64:3666–76.
14. Petri M, Wallace DJ, Spindler A et al. Sifalimumab, a human anti-interferon-alpha monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum 2013; 65:1011–21.
15. Herbst R, Liu Z, Jallal B et al. Biomarkers for systemic lupus erythematosus. Int J Rheum Dis 2012; 15:433–44.
16. Yao Y, Higgs BW, Richman L et al. Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus. Arthritis Res Ther 2010; 12 (Suppl. 1):S6.
17. Klein RQ, Bangert CA, Costner M et al. Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis. Br J Dermatol 2008; 159:887–94.
18. Yassaee M, Fiorentino D, Okawa J et al. Modification of the cutaneous dermatomyositis disease area and severity index, an outcome instrument. Br J Dermatol 2010; 162:669–73.
19. Goreshi R, Okawa J, Rose M et al. Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM. J Invest Dermatol 2012; 132:1117–24.
20. Anyanwu CO, Fiorentino DF, Chung L et al. Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index: characterizing disease severity and assessing responsiveness to clinical change. Br J Dermatol 2015; 173:969–74.
21. Babraham Bioinformatics. Available at: http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc/ (last accessed 4 March 2017).
22. Dobin A, Davis CA, Schlesinger F et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 2013; 29:15–21.
23. Harrow J, Frankish A, Gonzalez JM et al. GENCODE: the reference human genome annotation for the ENCODE Project. Genome Res 2012; 22:1760–74.
24. Risso D, Ngai J, Speed TP et al. Normalization of RNA-seq data using factor analysis of control genes or samples. Nat Biotechnol 2014; 32:896–902.
25. Antonelli G, Simeoni E, Turriziani O et al. Correlation of interferon-induced expression of MxA mRNA in peripheral blood mononuclear cells with the response of patients with chronic active hepatitis C to IFN-alpha therapy. J Interferon Cytokine Res 1999; 19:243–51.
26. Francois C, Bernard I, Castelain S et al. Quantification of different human alpha interferon subtypes and pegylated interferon activities by measuring MxA promoter activation. Antimicrob Agents Chemother 2005; 49:3770–5.
27. Foster GR, Masri SH, David R et al. IFN-alpha subtypes differentially affect human T cell motility. J Immunol 2004; 173:1663–70.
28. Lallemand C, Meritet JF, Erickson R et al. Quantification of neutralizing antibodies to human type I interferons using division-arrested frozen cells carrying an interferon-regulated reporter-gene. J Interferon Cytokine Res 2008; 28:393–404.
29. Reed AM, Peterson E, Bilgic H et al. Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course. Arthritis Rheum 2012; 64:4078–86.
30. Liao AP, Salajegheh M, Nazareno R et al. Interferon beta is associated with type 1 interferon-inducible gene expression in dermatomyositis. Ann Rheum Dis 2011; 70:831–6.
31. Isenberg DA, Allen E, Farewell V et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 2004; 43:49–54.
32. Hundley JL, Carroll CL, Lang W et al. Cutaneous symptoms of dermatomyositis significantly impact patients’ quality of life. J Am Acad Dermatol 2006; 54:217–20.
33. Goreshi R, Chock M, Foering K et al. Quality of life in dermatomyositis. J Am Acad Dermatol 2011; 65:1107–16.
34. Robinson ES, Feng R, Okawa J et al. Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life. Br J Dermatol 2015; 172:169–74.